FLT3 Mutations in Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: A Multi-Center Analysis
FLT3 mutations are established high-risk drivers in acute myeloid leukemia (AML), but their role in myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML) remains poorly defined. We assembled 115 patients with FLT3-mutant MDS (n=63) or CMML (n=52) across six academic institutions and compared clinicogenomic features and outcomes with FLT3-wildtype controls using propensity score matching and multivariable modeling. FLT3-mutant MDS and CMML displayed a proliferative phenotype, with higher white blood cell counts, increased frequency of CMML-2, and significantly higher rates of AML transformation. FLT3-mutant MDS was enriched for signaling co-mutations, such as NRAS, PTPN11, and CBL, whereas FLT3-mutant CMML showed frequent co-mutation with ASXL1 and SRSF2. FLT3 mutations were independently associated with inferior survival in both entities. After matching, FLT3-mutant MDS had worse median overall survival (OS: 19.9 vs 44.2 months, p=0.046) and leukemia-free survival (LFS: 13.8 vs 37.1 months, p=0.023). In CMML, median OS was 30.4 vs 67.2 months (p=0.017) and LFS 17.2 vs 65.6 months (p=0.014). FLT3-TKD was associated with more favorable outcomes than FLT3-ITD. FLT3-targeted therapy was associated with longer survival in unadjusted comparisons (median OS 14.3 vs 45.9 months in MDS; 20.6 vs 35.0 months in CMML), although this association was attenuated and no longer statistically significant after accounting for immortal time bias introduced from variable treatment initiation timing (adjusted time-dependent HR 0.66, MDS; 0.64, CMML). These findings support early identification of FLT3-mutant MDS and CMML and highlight the need for prospective studies evaluating early therapeutic intervention in this high-risk molecular subset.
Authors
- Sandra Castaño‐Díez (ORCID: https://orcid.org/0000-0001-9044-4665)
- Rami S. Komrokji (ORCID: https://orcid.org/0000-0002-1876-5269)
- David Valcárcel
- Jordi Esteve (ORCID: https://orcid.org/0000-0002-8056-648X)
- Xavier Calvo (ORCID: https://orcid.org/0000-0001-7934-9130)
- Guillermo Montalban‐Bravo (ORCID: https://orcid.org/0000-0002-4533-5176)
- Kelly Sharon Chien (ORCID: https://orcid.org/0000-0001-6024-1613)
- David Andrew Sallman (ORCID: https://orcid.org/0000-0003-0504-8233)
- Juan José Rodríguez‐Sevilla (ORCID: https://orcid.org/0000-0002-4741-7925)
- Eric Padron (ORCID: https://orcid.org/0000-0002-4707-7916)
- Clifford Michael Csizmar (ORCID: https://orcid.org/0000-0002-1221-8854)
- Rashmi Kanagal‐Shamanna (ORCID: https://orcid.org/0000-0001-7829-5249)
- Guillermo Garcia‐Manero (ORCID: https://orcid.org/0000-0002-3631-2482)
- María Díez‐Campelo (ORCID: https://orcid.org/0000-0002-1467-6779)
- Ruoxing Li (ORCID: https://orcid.org/0000-0003-4258-6321)
- Mrinal M. Patnaik (ORCID: https://orcid.org/0000-0001-6998-662X)
- Marina Díaz‐Beyá (ORCID: https://orcid.org/0000-0001-9624-2597)
- Francesc Gessé Solé (ORCID: https://orcid.org/0000-0002-3251-2161)
- Mónica Del Rey (ORCID: https://orcid.org/0000-0002-1048-8148)
- Ziyi Li (ORCID: https://orcid.org/0000-0001-8359-0533)
- Najla Al-Ali (ORCID: https://orcid.org/0009-0006-5212-5704)
- Andrés Jerez
- Maria Julia Montoro
- Marina Cornejo Garcia
- Abhishek A. Mangaonkar
- Fatima Zahra Jelloul
Institutions
- Mayo Clinic (US)
- The University of Texas MD Anderson Cancer Center (US)
- Universidad de Salamanca (ES)
- Moffitt Cancer Center (US)
- Josep Carreras Leukaemia Research Institute (ES)
- Hospital Clínic de Barcelona (ES)
- Vall d'Hebron Hospital Universitari (ES)
- Hospital Del Mar (ES)
- Instituto de Investigación Biomédica de Salamanca (ES)
- Centro de Investigación del Cáncer (ES)
- Consorci Institut D'Investigacions Biomediques August Pi I Sunyer (ES)
- Vall d'Hebron Institute of Oncology (ES)
- Fundació de Recerca Clínic Barcelona-Institut d’Investigacions Biomèdiques August Pi i Sunyer (ES)
Publication Details
- Journal
- Blood Advances
- Published
- 2026-11-20
- DOI
- https://doi.org/10.1182/bloodadvances.2026020859
- Primary Topic
- Acute Myeloid Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00